Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Prevalence of primary resistance mutations in patients with newly diagnosed HIV infection in the province of Málaga (Spain)].
Palacios R, Viciana I, Pérez de Pedro I, de la Torre J, Ropero F, Fernández S, Salgado F, Roldán J, de Dios Colmenero J, Márquez M, Santos J; Grupo Malagueño para el Estudio de las Enfermedades Infecciosas. Palacios R, et al. Enferm Infecc Microbiol Clin. 2008 Mar;26(3):141-5. doi: 10.1157/13116750. Enferm Infecc Microbiol Clin. 2008. PMID: 18358212 Spanish.
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E. Blanco JR, et al. Among authors: olalla j. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1403-204. HIV Clin Trials. 2013. PMID: 24144897
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study].
Viciana-Fernández P, Falcó V, Castaño M, de los Santos-Gil I, Olalla-Sierra J, Hernando A, Deig E, Clotet B, Knobel H, Podzamczer D, Pedrol PD; Grupo de trabajo Bridgap. Viciana-Fernández P, et al. Among authors: olalla sierra j. Enferm Infecc Microbiol Clin. 2015 Jun-Jul;33(6):397-403. doi: 10.1016/j.eimc.2014.06.012. Epub 2015 Jan 7. Enferm Infecc Microbiol Clin. 2015. PMID: 25577557 Spanish.
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR. Pedrol E, et al. Among authors: olalla j. HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. doi: 10.1179/1528433614Z.0000000001. Epub 2015 Jan 28. HIV Clin Trials. 2015. PMID: 25777189
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.
Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee. Iribarren JA, et al. Among authors: olalla j. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11. Enferm Infecc Microbiol Clin. 2016. PMID: 26976381
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.
Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee. Iribarren JA, et al. Among authors: olalla j. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Enferm Infecc Microbiol Clin. 2016. PMID: 27056581 Review.
144 results